PDF herunterladen
Gastroenterologie up2date 2012; 08(04): 291-312
DOI: 10.1055/s-0032-1325906
Leber/Galle/Pankreas
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Diagnostik und Therapie der Gallengangskarzinome – Update

Marcus W. Wiedmann
,
Sven Jonas
,
Joachim Mössner
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. Dezember 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik
Kernaussagen

Epidemiologie und Diagnostik

  • Gallengangskarzinome werden in Gallenblasenkarzinome, hiläre Gallengangskarzinome (Klatskin-Tumoren), distale extrahepatische Karzinome und intrahepatische Gallengangskarzinome unterteilt.

  • Während die Häufigkeit von intrahepatischen Gallengangs- und Papillenkarzinomen zunimmt, nimmt die Inzidenz von extrahepatischen Gallengangs- und Gallenblasenkarzinome dagegen ab.

  • Gallensteine stellen den Hauptrisikofaktor für die Entstehung von Gallenblasenkarzinomen dar (ca. 65 – 90 % der Patienten haben Gallensteine). Bei den Gallengangskarzinomen lassen sich dagegen nur in ca. 10 % Risikofaktoren finden.

  • Die Umwandlung von normalem in malignes Gallengangsgewebe unterliegt möglicherweise einer Reihe von aufeinanderfolgenden Genmutationen, ähnlich der Adenom-Dysplasie-Karzinom-Sequenz beim Kolonkarzinom.

  • Der abdominelle Ultraschall, die nicht invasive kombinierte Magnetresonanzcholangiografie/-tomografie (MRC/MRT), die Multidetektor-Computertomografie (MDCT) und die endoskopische retrograde Cholangiografie (ERC) stellen in der Primärdiagnostik den Goldstandard dar.

  • Beim Papillenkarzinom ist die Endosonografie neben der endoskopischen Biopsie diagnostisches Mittel der Wahl.

Therapie

  • Eine Heilung ist bei allen Tumorarten nur durch eine radikal-chirurgische Resektion im Gesunden möglich. Durch eine Zunahme der Radikalität konnte in den letzten Jahren eine deutliche Verbesserung der 5-Jahres-Überlebensraten erreicht werden.

  • Grundlegende Prinzipien der onkologischen Chirurgie sind die R0-Resektion mit weiten longitudinalen und lateralen Sicherheitsabständen, die Monobloc-Resektion des Tumors und die „No-touch“-Technik, d. h. ohne Manipulation am Tumor.

  • Die Frage eines klinischen Benefits für adjuvante Therapiemaßnahmen wird momentan in mehreren Studien untersucht.

  • In der Palliation ist die endoskopische und perkutane Drainage der Gallengänge fest etabliert. Der endosonografische Zugang stellt eine neue ergänzende Möglichkeit dar.

  • Die fotodynamische Therapie (PDT) ist eine wichtige Ergänzung der Drainage.

  • Während eine Radio- bzw. eine Radiochemotherapie in der Palliation nicht etabliert sind, gibt es mittlerweile einen neuen Standard im Bereich der Chemotherapie (Gemcitabin plus Cisplatin).

  • Zusätzliche molekulare Therapieziele werden zurzeit untersucht, es fehlen aber noch geeignete Biomarker für eine adäquate Patientenselektion.

 

  • Literatur

  • 1 de Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378
    CrossrefPubMedGoogle Scholar
  • 2 Wittekind C, Meyer HJ Hrsg. TNM: Klassifikation maligner Tumoren. 7.. Aufl. Weinheim: Wiley-VCH; 2010: 107-121
    Google Scholar
  • 3 Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215: 31-38
    CrossrefPubMedGoogle Scholar
  • 4 Wittekind C, Tannapfel A. Gallenblasen- und Gallengangskarzinoms – Biologie und Pathologie. Chir Gastroenterol 2004; 20: 242-249
    CrossrefPubMedGoogle Scholar
  • 5 Sakamoto E, Nimura Y, Hayakawa N et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg 1998; 227: 405-411
    CrossrefPubMedGoogle Scholar
  • 6 West J, Wood H, Logan RF et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 2006; 94: 1751-1758
    CrossrefPubMedGoogle Scholar
  • 7 Welzel TM, McGlynn KA, Hsing AW et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-875
    CrossrefPubMedGoogle Scholar
  • 8 Strom BL, Soloway RD, Rios-Dalenz JL et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 1995; 76: 1747-1756
    CrossrefPubMedGoogle Scholar
  • 9 Chow WH, Johansen C, Gridley G et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999; 79: 640-644
    CrossrefPubMedGoogle Scholar
  • 10 Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10: 308-311
    CrossrefPubMedGoogle Scholar
  • 11 Bergquist A, Glaumann H, Persson B et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 311-316
    CrossrefPubMedGoogle Scholar
  • 12 Shaib YH, El-Serag HB, Nooka AK et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-1021
    CrossrefPubMedGoogle Scholar
  • 13 Wadsworth CA, Dixon PH, Wong JH et al. Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011; 29: 93-97
    CrossrefPubMedGoogle Scholar
  • 14 Zen Y, Adsay NV, Bardadin K et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20: 701-709
    CrossrefPubMedGoogle Scholar
  • 15 Gouma DJ, Obertop H, Vismans J et al. Progression of a benign epithelial ampullary tumor to adenocarcinoma. Surgery 1987; 101: 501-504
    PubMedGoogle Scholar
  • 16 Andersen JB, Spee B, Blechacz BR et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142: 1021-1031
    Google Scholar
  • 17 Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969
    CrossrefPubMedGoogle Scholar
  • 18 Fava G, Marzioni M, Benedetti A et al. Molecular pathology of biliary tract cancers. Cancer Lett 2007; 250: 155-167
    CrossrefPubMedGoogle Scholar
  • 19 Fingas CD, Bronk SF, Werneburg NW et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011; 54: 2076-2088
    Google Scholar
  • 20 Olaru AV, Ghiaur G, Yamanaka S et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011; 54: 2089-2098
    CrossrefPubMedGoogle Scholar
  • 21 Selaru FM, Olaru AV, Kan T et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49: 1595-1601
    CrossrefPubMedGoogle Scholar
  • 22 Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2011; 17: 72-79
    PubMedGoogle Scholar
  • 23 Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011; 7: 517-535
    PubMedGoogle Scholar
  • 24 Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma?. Oncologist 2006; 11: 913-922
    CrossrefPubMedGoogle Scholar
  • 25 Barr Fritcher EG, Kipp BR, Voss JS et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol 2011; 106: 2023-2028
    CrossrefPubMedGoogle Scholar
  • 26 Lankisch TO, Metzger J, Negm AA et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011; 53: 875-884
    CrossrefPubMedGoogle Scholar
  • 27 Itoi T, Sofuni A, Itokawa F et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 2007; 66: 730-736
    CrossrefPubMedGoogle Scholar
  • 28 Draganov PV, Lin T, Chauhan S et al. Prospective evaluation of the clinical utility of ERCP-guided cholangiopancreatoscopy with a new direct visualization system. Gastrointest Endosc 2011; 73: 971-979
    CrossrefPubMedGoogle Scholar
  • 29 Pohl J, Ell C. Direct transnasal cholangioscopy with ultraslim endoscopes: a one-step intraductal balloon-guided approach. Gastrointest Endosc 2011; 74: 309-316
    CrossrefPubMedGoogle Scholar
  • 30 Arvanitakis M, Hookey L, Tessier G et al. Intraductal optical coherence tomography during endoscopic retrograde cholangiopancreatography for investigation of biliary strictures. Endoscopy 2009; 41: 696-701
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 31 Imazu H, Uchiyama Y, Matsunaga K et al. Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. Scand J Gastroenterol 2011; 45: 732-738
    PubMedGoogle Scholar
  • 32 Ruys AT, Bennink RJ, van Westreenen HL et al. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. HPB (Oxford) 2011; 13: 256-262
    CrossrefPubMedGoogle Scholar
  • 33 Ruys AT, Busch OR, Gouma DJ et al. Staging laparoscopy for hilar cholangiocarcinoma: is it still worthwhile?. Ann Surg Oncol 2011; 18: 2647-2653
    CrossrefPubMedGoogle Scholar
  • 34 D’Angelica M, Dalal KM, DeMatteo RP et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol 2009; 16: 806-816
    CrossrefPubMedGoogle Scholar
  • 35 Tischoff I, Tannapfel A. Hepatozelluläres Karzinom und Cholangiokarzinom – Unterschiedliche Prognose, Pathogenese und Therapie. Zentralbl Chir 2007; 132: 300-305
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 36 Knuppel M, Kubicka S, Vogel A et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. Gastroenterol Res Pract 2012; 2012: 190708
    PubMedGoogle Scholar
  • 37 Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006; 45: 856-867
    CrossrefPubMedGoogle Scholar
  • 38 Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96
    CrossrefPubMedGoogle Scholar
  • 39 Stockmann M, Lock JF, Malinowski M et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010; 12: 139-146
    CrossrefPubMedGoogle Scholar
  • 40 Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314
    CrossrefPubMedGoogle Scholar
  • 41 Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667
    CrossrefPubMedGoogle Scholar
  • 42 Liu F, Li Y, Wei Y et al. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011; 56: 663-672
    CrossrefPubMedGoogle Scholar
  • 43 Kawakami H, Kondo S, Kuwatani M et al. Preoperative biliary drainage for hilar cholangiocarcinoma: which stent should be selected?. J Hepatobiliary Pancreat Sci 2011; 18: 630-635
    CrossrefPubMedGoogle Scholar
  • 44 Jean M, Dua K. Tumors of the ampulla of Vater. Curr Gastroenterol Rep 2003; 5: 171-175
    CrossrefPubMedGoogle Scholar
  • 45 Misra S, Chaturvedi A, Misra NC et al. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176
    CrossrefPubMedGoogle Scholar
  • 46 Cho SY, Kim SH, Park SJ et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 2010; 102: 87-93
    CrossrefPubMedGoogle Scholar
  • 47 Takada T, Amano H, Yasuda H et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695
    CrossrefPubMedGoogle Scholar
  • 48 Wang SJ, Lemieux A, Kalpathy-Cramer J et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011; 29: 4627-4632
    CrossrefPubMedGoogle Scholar
  • 49 Fuller CD, Wang SJ, Choi M et al. Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis. Cancer 2009; 115: 5175-5183
    CrossrefPubMedGoogle Scholar
  • 50 Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol 2005; 14: 59-74
    CrossrefPubMedGoogle Scholar
  • 51 Speer AG, Cotton PB, Russel RC et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
    CrossrefPubMedGoogle Scholar
  • 52 Will U, Meyer F. [Endoscopic ultrasonography (EUS)-guided transluminal cholangiodrainage (EUCD) – a novel option of interventional endoscopy in the interdiciplinary management of obstructive jaundice]. Zentralbl Chir 2012; 137: 20-31
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 53 Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 165-175
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 54 Valek V, Kysela P, Kala Z et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007; 62: 175-179
    CrossrefPubMedGoogle Scholar
  • 55 Baron TH. Photodynamic therapy: standard of care for palliation of cholangiocarcinoma?. Clin Gastroenterol Hepatol 2008; 6: 266-267
    CrossrefPubMedGoogle Scholar
  • 56 Ortner MEJ, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363
    CrossrefPubMedGoogle Scholar
  • 57 Zoepf T, Jakobs R, Arnold JC et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430
    CrossrefPubMedGoogle Scholar
  • 58 Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281
    Google Scholar
  • 59 Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-4586
    CrossrefPubMedGoogle Scholar
  • 60 Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600
    CrossrefPubMedGoogle Scholar
  • 61 Rao S, Cunningham D, Hawkins RE et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92: 1650-1654
    CrossrefPubMedGoogle Scholar
  • 62 Wiedmann MW, Mossner J. Molecular targeted therapy of biliary tract cancer – results of the first clinical studies. Curr Drug Targets 2010; 11: 834-850
    Google Scholar